within Pharmacolibrary.Drugs.S_SensoryOrgans.S01B_AntiinflammatoryAgents.S01BC05_Ketorolac;

model Ketorolac
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 6.805555555555556e-06,
    adminDuration = 600,
    adminMass = 30 / 1000000,
    adminCount = 1,
    Vd = 0.013,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0067,
    k12 = 1.2777777777777777e-06,
    k21 = 1.2777777777777777e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Ketorolac</td></tr><tr><td>ATC code:</td><td>S01BC05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>30</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>13</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.35</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) used for short-term management of moderate to severe pain, commonly following surgeries. It works by inhibiting cyclooxygenase (COX) enzymes, reducing the synthesis of prostaglandins. Ketorolac is approved for use in many countries and is available in oral, intravenous, intramuscular, and ophthalmic formulations. The ATC code S01BC05 refers specifically to its ophthalmic (eye drop) formulation for the treatment of eye pain and inflammation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects, intravenous administration.</p><h4>References</h4><ol><li><p>McLay, JS, et al., &amp; Anderson, BJ (2018). The pharmacokinetics of intravenous ketorolac in children aged 2 months to 16 years: A population analysis. <i>Paediatric anaesthesia</i> 28(2) 80–86. DOI:<a href=\"https://doi.org/10.1111/pan.13302\">10.1111/pan.13302</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29266539/\">https://pubmed.ncbi.nlm.nih.gov/29266539</a></p></li><li><p>Mohammed, BS, et al., &amp; McLay, JS (2015). The enantioselective population pharmacokinetics of intravenous ketorolac in children using a stereoselective assay suitable for microanalysis. <i>The Journal of pharmacy and pharmacology</i> 67(9) 1179–1187. DOI:<a href=\"https://doi.org/10.1111/jphp.12418\">10.1111/jphp.12418</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25880462/\">https://pubmed.ncbi.nlm.nih.gov/25880462</a></p></li><li><p>Cohen, MN, et al., &amp; Galinkin, J (2011). Pharmacokinetics of single-dose intravenous ketorolac in infants aged 2-11 months. <i>Anesthesia and analgesia</i> 112(3) 655–660. DOI:<a href=\"https://doi.org/10.1213/ANE.0b013e3182075d04\">10.1213/ANE.0b013e3182075d04</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21233498/\">https://pubmed.ncbi.nlm.nih.gov/21233498</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.S.S01BC05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Ketorolac;
